Skip to main content

Market Overview

Veru's FC2 Prescription Sales Boost Q2 Revenues

Veru's FC2 Prescription Sales Boost Q2 Revenues
  • Veru Inc (NASDAQ: VERUreported a Q1 EPS loss of ($0.04), which met the analyst consensus estimate. The loss is wider than ($0.01) net loss a year ago.
  • Sales for the quarter were reported at $13.3 million, up 34% Y/Y, but missed the analyst consensus estimate of $14.29 million.
  • FC2 prescription net revenues from the U.S. prescription channel climbed 48% Y/Y to $10.3 million.
  • Gross profit rose 47% Y/Y to $10.9 million, with a gross margin expansion to 82% from 75% last year.
  • Operating loss was $1.5 million versus $0.3 million last year.
  • Price Action: VERU shares are up 1.34% at $7.59 during the premarket session on the last check Wednesday.

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Guidance Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at